Objective: Alcoholic acute-on-chronic liver failure (ACLF) is a unique clinical entity that is characterized by acute onset, poor prognosis and high short-term mortality. There is no specific and effective treatment for this disease, except liver transplantation.
INTRODUCTION
Alcoholic liver disease (ALD) is one of the most common diagnoses among liver diseases in Europe and the United States. (1) In China, ALD is the most increasing liver diseases in recent years.(2) Some patients with chronic ALD may rapidly progress towards acute-on-chronic liver failure (ACLF), which is a severe, life-threatening condition, for which liver transplantation is the standard treatment.(3) However, there is a prevailing contradiction between the urgent need for liver transplants and a severe shortage of donor livers, which highlights the necessity to develop new therapeutic strategies for these conditions. Mesenchymal stem cells (MSCs) are multipotent with self-renewal abilities and the potential to differentiate into various types of cells, including hepatocytes.(4) MSCs have been investigated and clinically used in numerous immune-mediated or inflammatory diseases such as acute GVHD. (5) MSCs have also been used in clinical trials for treatment of liver diseases. Infusions of autologous Bone marrow (BM)-MSCs or umbilical cord (UC)-MSCs have significantly improved liver function in patients with liver cirrhosis (6-8) and liver failure.(9, 10) To explore alternative approaches for treatment of liver diseases, we tried MSC therapies in selected patients. Herein, we report the case of an alcoholic ACLF patient who recovered due to MSC treatment, as indicated by decreased jaundice, normalized TBIL level and decreased Child's Pugh scores. A literature review on MSC treatment of liver diseases was also conducted.
SUBJECTS AND METHODS

Umbilical-cord-derived MSC preparation, culture and identification
The umbilical cords (UCs) were dissected after thorough washing, and the blood vessels were removed. The use of UCs was approved by the Ethics Committee of Qilu hospital of Shandong University, and written informed consent from the donors was provided by the department of obstetrics at Qilu hospital of Shandong university. The remaining tissues were cut into small pieces (1-2 mm 3 ) and cultured in plates with L-DMEM, supplemented with 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37 °C with 5% CO2. After 7-12 days, the tissue pieces were removed and the adherent fibroblast-like cells were cultured to confluence. The cells were then passaged at 1×10 4 cells/cm 2 in the medium and used after five or more passages.
Fifth-to seventh-passage cells were collected and treated with 0.25% trypsin.
Subsequently, the cells were stained with either fluorescein-isothiocyanate-conjugated or phycoerythrin-conjugated monoclonal antibodies in 100 µL of phosphate buffer for 15 min at room temperature, as suggested by the manufacturer. The antibodies used were against human antigens CD29, CD31, CD34, CD45, CD44, CD73, CD90, CD105, and CD271 (BD Pharmingen, USA). The cells were analyzed with a flow cytometer (Guava easyCyte8HT, EMD Millipore, Billerica, USA), and the data were examined with Guava Incyte (EMD Millipore). Positive cells were counted and compared with the signal of corresponding immunoglobulin isotypes.
Case
A 41-year-old man (Han Chinese worker) was admitted to our hospital with right upper quadrant pain and worsening jaundice. The patient was usually in good health, denied other disease history, or long-term use of drugs, or history of Chinese herbal medicine or health products usage, or toxic exposure. His father was healthy, and mother had high blood pressure. Seven days ago, he suddenly had a fever (37.7 ℃) and jaundice, with alanine Ultrasonography of the abdomen showed massive ascites. A CT scan of the abdomen without intravenous contrast further delineated that the liver volume was enlarged with heterogeneous density (Figure 1 ). The patient had a history of drinking more than 150 g ethyl alcohol each day for more than 20 years, and smoking 15 cigarettes each day for more than 15 years. Other chronic liver disease etiologies were found through serum tests and case history including hepatitis B, C, D and E virus, CMV, EBV and HIV infection, drug-induced liver injury, and autoimmune liver diseases. Table 1 summarizes the main liver function tests. Based on these clinical presentations, and the results of laboratory and physical examinations, the patient was diagnosed as alcoholic ACLF.
After admission to our hospital, the patient was treated with liver protection and antiinfection remedies for 14 days but did not respond. He was subsequently given plasma exchange, bilirubin adsorption and artificial liver treatment at 3-day intervals for 45 days.
After each plasma exchange or artificial liver treatment, serum total bilirubin levels transiently decreased but quickly rebound to the pre-treatment levels. Following this period, he had repeated occurrence of fever, rash, anemia, electrolyte imbalance, continuous jaundice and serum TBIL > 450 μmol/L. Liver transplantation was considered but not performed due to lack of matched donor liver. Further treatments including venous, hypodemic and intramuscular injected drugs, plasma exchange and artificial liver were refused by the patient's family. After informed consent from the patient and approval by the ethics committee of our hospital, the UC-MSCs treatment was applied.
Mesenchymal stem cells-based treatment scheme
Before MSCs treatment, the patient was treated with glutathione, ornithine aspartate, compound glycyrrhizin, ursodesoxycholic acid for anti-oxidation and protecting liver and gallbladder functions, and efperazone-sulbactam and imipenem for anti-infection.
Furthermore, plasma exchange treatment was given ten times. In two months, the patient developed recurrent fever, which was identified as drug-induced fever, although the specific drugs were not identified. Since the patient usually developed fever after intravenous treatment, we stopped all intravenous drugs and started cell therapy, in which the patient only took oral compound amino acid and ursodesoxycholic acid. UC-MSCs at a dose of 2.5×10 7 were intravenously administered, after approval from our hospital's IRB. No side-effects were observed during this treatment. The second and third clonal UC-MSCs were given one week and two weeks after the first infusion at the dose of 3.0×10 7 , respectively.
RESULT
After several passages, the adherent cells from UC could form a monolayer of typical fibroblast and plastic-adherent cells ( Fig. 2A) . H&E staining showed spindle-shaped cells (Fig. 2C) . These results indicated that the cells were undifferentiated and had stem cell characteristics.
Three weeks after the onset of MSC treatment, the patient's jaundice began to decrease, with normalized TBIL level. Other biochemical examinations also returned to normal during the following 24 weeks ( Table 1 ). The patient finally recovered.
ACLF is a unique clinical entity that is characterized by acute onset, poor prognosis and high short-term mortality. Generally, it occurs as a result of various chronic hepatic injuries and usually displays sequential and overlapping severe pathogenic processes that include severe inflammation, hepatocyte necrosis and fibrosis/cirrhosis. (9, 11) Liver transplantation is the standard treatment for such patients. However, limited numbers of donors, long waiting lists, high cost, and multiple complications (such as rejection, problems associated with the longterm use of immunosuppressants, and perioperative morbidity and mortality) have restricted the use of liver transplantation in many ACLF patients. Therefore, new strategies to delay or prevent progression of liver failure are urgently required. 
